Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis

Matz, Ethan; Hsieh, Michael H.

doi:10.1016/j.urology.2016.07.030

Cited by 102 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vigorous hydration to increase urine output and intravenous 2-mercaptethane sulfonate (MESNA) were recommended for prophylaxis of cyclophosphamide-induced hemorrhagic cystitis (C) [38].…”

Section: How Long Should Sam Patients Receive Immunosuppressive / Immmentioning

confidence: 99%

Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies

et al. 2019

View full text Add to dashboard Cite

Background: Recommendations of the Myopathy Committee of the Brazilian Society of Rheumatology for the management and therapy of systemic autoimmune myopathies (SAM). Main body: The review of the literature was done in the search for the Medline (PubMed), Embase and Cochrane databases including studies published until June 2018. The Prisma was used for the systematic review and the articles were evaluated according to the levels of Oxford evidence. Ten recommendations were developed addressing the management and therapy of systemic autoimmune myopathies. Conclusions: Robust data to guide the therapeutic process are scarce. Although not proven effective in controlled clinical trials, glucocorticoid represents first-line drugs in the treatment of SAM. Intravenous immunoglobulin is considered in induction for refractory cases of SAM or when immunosuppressive drugs are contra-indicated. Consideration should be given to the early introduction of immunosuppressive drugs. There is no specific period determined for the suspension of glucocorticoid and immunosuppressive drugs when individually evaluating patients with SAM. A key component for treatment in an early rehabilitation program is the inclusion of strengthbuilding and aerobic exercises, in addition to a rigorous evaluation of these activities for remission of disease and the education of the patient and his/her caregivers.

show abstract

“…Vigorous hydration to increase urine output and intravenous 2-mercaptethane sulfonate (MESNA) were recommended for prophylaxis of cyclophosphamide-induced hemorrhagic cystitis (C) [38].…”

Section: How Long Should Sam Patients Receive Immunosuppressive / Immmentioning

confidence: 99%

Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The metabolism of cyclophosphamide and ifosfamide generates acrolein, a compound that is secreted through the urine and can cause urothelial damage upon storage in the bladder [3]. Concurrent treatment with Mesna, or other uroprotective agents, can minimize acrolein-induced damage to the bladder [4]. Cyclophosphamide and ifosfamide are not commonly used for the treatment of genital cancers, thus little is known about long-term side effects of these drugs in genital cancer survivors [5].…”

Section: Introductionmentioning

confidence: 99%

Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This condition affects up to 40% of ifosfamide-exposed patients, resulting in hematuria, dysuria, bladder spasms, and urinary frequency (9). Hemorrhagic cystitis is a challenging condition to manage, and often requires hospitalization and invasive treatments (16).…”

Section: Introductionmentioning

confidence: 99%

“…Accordingly, strategies to attenuate ifosfamide-induced hemorrhagic cystitis, such as administration of 2-mercaptoethanesulfonic acid (MESNA), bladder irrigation, or hyperhydration often achieve suboptimal protection for patients (16). Despite use of existing therapies, a majority of patients have symptomatic and/or histologic evidence of hemorrhagic cystitis (14).…”

Section: Introductionmentioning

confidence: 99%

IPSE, a parasite-derived host immunomodulatory protein, is a promising therapeutic for hemorrhagic cystitis

Zee

Mbanefo

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

1Chemotherapy-induced hemorrhagic cystitis is characterized by bladder pain and 2 voiding dysfunction caused by hemorrhage and inflammation. Of currently available 3 therapies, prophylactic 2-mercaptoethanesulfonic acid (MESNA) has limited efficacy 4 and cannot treat pre-existing lesions. Therefore, novel therapeutic options to treat 5 hemorrhagic cystitis are needed. We previously reported that systemic administration of 6 the Schistosomiasis haematobium-derived protein H-IPSE H06 (IL-4-inducing principle 7 from Schistosoma mansoni eggs), is superior to 3 doses of MESNA in alleviating 8 hemorrhagic cystitis. Based on prior reports by others on S. mansoni IPSE and 9 additional work by our group, we reasoned that H-IPSE H06 mediates its effects on 1 0 hemorrhagic cystitis by binding IgE on basophils and inducing IL-4 expression, 1 1promoting urothelial proliferation, and translocating to the nucleus to modulate 1 2 expression of genes implicated in relieving bladder dysfunction. We speculated that 1 3 local bladder injection of the S. haematobium IPSE ortholog IPSE H03 , hereafter called H-1 4 IPSE H03 , might be more efficacious in preventing hemorrhagic cystitis compared to 1 5 systemic administration of IPSE H06 . We demonstrate herein that H-IPSE H03 is a 1 6promising therapeutic for the treatment of voiding dysfunction and bladder pain in 1 7 hemorrhagic cystitis. Namely, it attenuates ifosfamide-induced increases in bladder wet 1 8 weight in an IL-4-dependent fashion. H-IPSE H03 relieves hemorrhagic cystitis-associated 1 9 allodynia. Finally, H-IPSE H03 drives increased urothelial cell proliferation. This indicates 2 0that IPSE induces bladder healing mechanisms, which suggests that it may be a novel 2 1 non-opioid analgesic to treat bladder pain syndromes. 2 2 4 1 demonstrated fewer spontaneous pain behaviors and had a higher threshold for evoked 4 2pain responses. We speculated that direct injection of IPSE into the bladder wall would 4 3 have multiple advantages over intravenous injection, including avoidance of side effects 4 4 caused by systemic administration (although none have been identified to date), and 4 5 potentially decreased dosage to achieve a therapeutic effect. The aim of this work was 4 6

show abstract

Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis

Cited by 102 publications

References 27 publications

Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies

Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies

Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies

IPSE, a parasite-derived host immunomodulatory protein, is a promising therapeutic for hemorrhagic cystitis

Contact Info

Product

Resources

About